Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 8/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31756925 | 0.93 | PTPN1 (0.40) | APLNRERAP2BACE1BACE2NPY1R | |
| SCHEMBL31573788 | 0.90 | FOLH1 (0.36) | APLNRERAP2FOLH1BACE1BACE2 | |
| SCHEMBL29833168 | 0.90 | BACE1 (0.45) | ERAP2BACE1BACE2NPY1RNPY2R | |
| SCHEMBL29519893 | 0.89 | ERAP2 (0.58) | ERAP2 | |
| SCHEMBL30211127 | 0.89 | FOLH1 (0.40) | FOLH1 | |
| SCHEMBL29833346 | 0.88 | PTPN1 (0.45) | ERAP2BACE1BACE2NPY1RNPY2R | |
| SCHEMBL30167454 | 0.88 | ERAP2 (0.45) | ERAP2FOLH1BACE1BACE2NPY1R | |
| SCHEMBL29689307 | 0.87 | BACE1 (0.45) | APLNRBACE1BACE2CTSD | |
| SCHEMBL29511067 | 0.87 | MME (0.45) | ERAP2NPY1RNPY2RNPY4RMME | |
| SCHEMBL30066857 | 0.87 | MME (0.47) | NPY1RNPY2RNPY4RMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124612-A1 | MOLECULES WITH ALTERED NEONATE FC RECEPTOR BINDING HAVING ENHANCED THERAPEUTIC AND DIAGNOSTIC PROPERTIES | MEDIMMUNE LLC | 2024-04-18 | — | — | US | disclosed |
| US-11767369-B2 | Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties | MEDIMMUNE, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| CN-106413750-B | Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties | 免疫医疗有限责任公司 | 2022-04-29 | — | — | CN | disclosed |